Stem Cell Transplant for Children with Sickle Cell Anemia

Parent and Patient Interest

Michael Roth, Julie Krystal, Deepa G. Manwani, Catherine Driscoll, Rosanna Ricafort

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We describe adolescents' and parents' interest in hematopoietic stem cell transplant (HSCT) as a cure for sickle cell disease (SCD) and factors associated with increased interest. We administered a 40 question survey to assess the interest in HSCT in parents and adolescents with HBSS or HBSβ0 thalassemia. The survey tool assessed factors that may influence interest in HSCT including demographic data, disease severity, views on prognosis, and health-related quality of life (HRQOL). All participants were given a handout on the risks and benefits of an HSCT before completing the survey. One hundred twenty-nine parents and 59 adolescents completed the survey. Forty-five percent of parents (54 of 119) would likely have their child undergo HSCT, and 35% of adolescents (19 of 55) would likely undergo HSCT if it was recommended by their hematologist. Parents of adolescents, as well as adolescent patients with better HRQOL, were more interested in HSCT. Prior exchange transfusion was associated with increased interest in HSCT (62% [23 of 37] versus 38% [29 of 76]; P = .02). The majority of parents believe their child's SCD will get better (66%; [80 of 122]), will not likely prevent their child from achieving life goals (83%; [100 of 121]), and will not shorten their child's lifespan (86%; [102 of 119]). There is strong parent and adolescent interest in HSCT as a cure for SCD. It is concerning that few parents and adolescents believe SCD will negatively impact their prognosis. Education on the potential long-term sequelae of SCD is needed when considering the role for HSCT.

Original languageEnglish (US)
Pages (from-to)1709-1715
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Sickle Cell Anemia
Hematopoietic Stem Cells
Stem Cells
Transplants
Parents
Quality of Life
Thalassemia
Demography
Education
Surveys and Questionnaires

Keywords

  • Hematopoietic stem cell transplant
  • Prognosis
  • Quality of life
  • Sickle cell disease

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Stem Cell Transplant for Children with Sickle Cell Anemia : Parent and Patient Interest. / Roth, Michael; Krystal, Julie; Manwani, Deepa G.; Driscoll, Catherine; Ricafort, Rosanna.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 11, 11.2012, p. 1709-1715.

Research output: Contribution to journalArticle

Roth, Michael ; Krystal, Julie ; Manwani, Deepa G. ; Driscoll, Catherine ; Ricafort, Rosanna. / Stem Cell Transplant for Children with Sickle Cell Anemia : Parent and Patient Interest. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 11. pp. 1709-1715.
@article{1dcbe54c77b54b0f912766c47a2310ec,
title = "Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest",
abstract = "We describe adolescents' and parents' interest in hematopoietic stem cell transplant (HSCT) as a cure for sickle cell disease (SCD) and factors associated with increased interest. We administered a 40 question survey to assess the interest in HSCT in parents and adolescents with HBSS or HBSβ0 thalassemia. The survey tool assessed factors that may influence interest in HSCT including demographic data, disease severity, views on prognosis, and health-related quality of life (HRQOL). All participants were given a handout on the risks and benefits of an HSCT before completing the survey. One hundred twenty-nine parents and 59 adolescents completed the survey. Forty-five percent of parents (54 of 119) would likely have their child undergo HSCT, and 35{\%} of adolescents (19 of 55) would likely undergo HSCT if it was recommended by their hematologist. Parents of adolescents, as well as adolescent patients with better HRQOL, were more interested in HSCT. Prior exchange transfusion was associated with increased interest in HSCT (62{\%} [23 of 37] versus 38{\%} [29 of 76]; P = .02). The majority of parents believe their child's SCD will get better (66{\%}; [80 of 122]), will not likely prevent their child from achieving life goals (83{\%}; [100 of 121]), and will not shorten their child's lifespan (86{\%}; [102 of 119]). There is strong parent and adolescent interest in HSCT as a cure for SCD. It is concerning that few parents and adolescents believe SCD will negatively impact their prognosis. Education on the potential long-term sequelae of SCD is needed when considering the role for HSCT.",
keywords = "Hematopoietic stem cell transplant, Prognosis, Quality of life, Sickle cell disease",
author = "Michael Roth and Julie Krystal and Manwani, {Deepa G.} and Catherine Driscoll and Rosanna Ricafort",
year = "2012",
month = "11",
doi = "10.1016/j.bbmt.2012.05.013",
language = "English (US)",
volume = "18",
pages = "1709--1715",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Stem Cell Transplant for Children with Sickle Cell Anemia

T2 - Parent and Patient Interest

AU - Roth, Michael

AU - Krystal, Julie

AU - Manwani, Deepa G.

AU - Driscoll, Catherine

AU - Ricafort, Rosanna

PY - 2012/11

Y1 - 2012/11

N2 - We describe adolescents' and parents' interest in hematopoietic stem cell transplant (HSCT) as a cure for sickle cell disease (SCD) and factors associated with increased interest. We administered a 40 question survey to assess the interest in HSCT in parents and adolescents with HBSS or HBSβ0 thalassemia. The survey tool assessed factors that may influence interest in HSCT including demographic data, disease severity, views on prognosis, and health-related quality of life (HRQOL). All participants were given a handout on the risks and benefits of an HSCT before completing the survey. One hundred twenty-nine parents and 59 adolescents completed the survey. Forty-five percent of parents (54 of 119) would likely have their child undergo HSCT, and 35% of adolescents (19 of 55) would likely undergo HSCT if it was recommended by their hematologist. Parents of adolescents, as well as adolescent patients with better HRQOL, were more interested in HSCT. Prior exchange transfusion was associated with increased interest in HSCT (62% [23 of 37] versus 38% [29 of 76]; P = .02). The majority of parents believe their child's SCD will get better (66%; [80 of 122]), will not likely prevent their child from achieving life goals (83%; [100 of 121]), and will not shorten their child's lifespan (86%; [102 of 119]). There is strong parent and adolescent interest in HSCT as a cure for SCD. It is concerning that few parents and adolescents believe SCD will negatively impact their prognosis. Education on the potential long-term sequelae of SCD is needed when considering the role for HSCT.

AB - We describe adolescents' and parents' interest in hematopoietic stem cell transplant (HSCT) as a cure for sickle cell disease (SCD) and factors associated with increased interest. We administered a 40 question survey to assess the interest in HSCT in parents and adolescents with HBSS or HBSβ0 thalassemia. The survey tool assessed factors that may influence interest in HSCT including demographic data, disease severity, views on prognosis, and health-related quality of life (HRQOL). All participants were given a handout on the risks and benefits of an HSCT before completing the survey. One hundred twenty-nine parents and 59 adolescents completed the survey. Forty-five percent of parents (54 of 119) would likely have their child undergo HSCT, and 35% of adolescents (19 of 55) would likely undergo HSCT if it was recommended by their hematologist. Parents of adolescents, as well as adolescent patients with better HRQOL, were more interested in HSCT. Prior exchange transfusion was associated with increased interest in HSCT (62% [23 of 37] versus 38% [29 of 76]; P = .02). The majority of parents believe their child's SCD will get better (66%; [80 of 122]), will not likely prevent their child from achieving life goals (83%; [100 of 121]), and will not shorten their child's lifespan (86%; [102 of 119]). There is strong parent and adolescent interest in HSCT as a cure for SCD. It is concerning that few parents and adolescents believe SCD will negatively impact their prognosis. Education on the potential long-term sequelae of SCD is needed when considering the role for HSCT.

KW - Hematopoietic stem cell transplant

KW - Prognosis

KW - Quality of life

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84867488154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867488154&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.05.013

DO - 10.1016/j.bbmt.2012.05.013

M3 - Article

VL - 18

SP - 1709

EP - 1715

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -